secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0001640334-23-001812
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria shareholders approve reverse stock split; company granted two Canadian patents
--------------------------------------------------------------------------------

- Shareholders approved reverse stock split with ratio between 2:1 and 12:1 (67% for).
- Entered 3-month investor relations contract with Andrew Barwicki Inc. for $99,500.
- Granted Canadian patent for DehydraTECH in ready-to-drink beverages (expires Dec 2036).
- Granted Canadian patent for tobacco leaves infused with lipophilic agents (expires Sep 2039).
- Total granted patents now 37 worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423001812/0001640334-23-001812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423001812/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-23-001812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer